

Susana Rosello Keranen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9055590/susana-rosello-keranen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

2,019
citations

25
h-index

43
g-index

87
ext. papers

2,526
ext. citations

5.4
avg, IF

4.48
L-index

#	Paper	IF	Citations
75	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021 , 30, 2455	3.9	1
74	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2021 ,	12.9	14
73	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021 , 11, 712053	5.3	3
72	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	4
71	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021 , 13,	6.6	7
70	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021 , 125, 1261-1269	8.7	4
69	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 227-235	3.8	2
68	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
67	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
66	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020 , 43, 63-72	0.1	
65	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102015	14.4	75
64	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020 , 12,	6.6	39
63	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4009-4009	2.2	3
62	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology</i> , 2020 , 43, 63-72	0.9	1
61	The actual management of colorectal liver metastases. <i>Minerva Chirurgica</i> , 2020 , 75, 328-344	0.8	
60	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020 , 5, e000847	6	6
59	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7

58	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , 2020 , 5, e000929	6	2
57	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2020 , 4, e000813	6	20
56	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , 2020 , 146, 94-102	7.5	15
55	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019 , 4, e000476	6	15
54	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , 2019 , 30, 1804-1812	10.3	64
53	Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. <i>Histopathology</i> , 2019 , 75, 517-525	7.3	3
52	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019 , 30, 1254-1264	10.3	11
51	Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019 , 62, 684-693	3.1	16
50	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. <i>Modern Pathology</i> , 2019 , 32, 306-313	9.8	16
49	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 1639-1649	12.9	30
48	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , 2018 , 63, 156-171	14.4	26
47	Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 104-112.e2	3.8	10
46	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 124-135	14.4	17
45	Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 935-943	3.5	6
44	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. <i>Clinical Lung Cancer</i> , 2017 , 18, e395-e402	4.9	25
43	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 1478-1485	8.7	64
42	Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2017 , 28, iv100-iv118	10.3	49
41	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017 , 7, 102-113	24.4	105

40	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 449-56	5.5	6
39	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016 , 7, 63424-63436	3.3	12
38	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016 , 7, 22543-55	3.3	9
37	SEOM Clinical Guideline of localized rectal cancer (2016). <i>Clinical and Translational Oncology</i> , 2016 , 18, 1163-1171	3.6	5
36	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , 2016 , 18, 41	6.3	11
35	Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment. <i>Clinical and Translational Oncology</i> , 2015	3.6	7
34	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 303-12	4	13
33	Extending neoadjuvant chemotherapy in rectal cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 880-1	21.7	1
32	Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. <i>Diseases of the Colon and Rectum</i> , 2015 , 58, 556-65	3.1	24
31	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0130543	3.7	8
30	Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015 , 6, 26935-45	3.3	30
29	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1874-81	8.7	25
28	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , 2015 , 5, 598-609	24.4	65
27	RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. <i>European Journal of Cancer</i> , 2014 , 50, 1430-6	7.5	26
26	Prognostic Implications of the Standardized Study of Resection Margins in Pancreatic Cancers. <i>Cirugía Española (English Edition)</i> , 2014 , 92, 532-538	0.1	
25	Prognostic implications of the standardized study of resection margins in pancreatic cancers. <i>Cirugía Española</i> , 2014 , 92, 532-8	0.7	11
24	FcRIIIa and FcRIIIa polymorphisms and cetuximab benefit in the microscopic disease. <i>Clinical Cancer Research</i> , 2014 , 20, 4511-9	12.9	7
23	Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3551-3551	2.2	

22	FCBIIa and FCBIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3573-3573	2.2	
21	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 60-7	14.4	133
20	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 4764-74	12.9	119
19	Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14589-e14589	2.2	
18	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1074-1074	2.2	
17	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , 2011 , 117, 3118-25	6.4	76
16	A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 6304-12	12.9	102
15	Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. <i>Cancer Research</i> , 2011 , 71, 675-85	10.1	36
14	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , 2010 , 21, 1537-1545	10.3	62
13	Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 2844-52	6.1	73
12	Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1181-9	2.2	99
11	The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment. <i>Clinical and Translational Oncology</i> , 2010 , 12, 339-45	3.6	10
10	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 245-51	4.4	45
9	Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 479-84	4.4	125
8	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , 2009 , 11, 787-98	3.6	31
7	Pancreatic and periampullary tumours: morbidity, mortality, functional results, and long-term survival. <i>Cirugía Española (English Edition)</i> , 2009 , 86, 159-166	0.1	
6	Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. <i>British Journal of Cancer</i> , 2008 , 99, 455-8	8.7	48
5	279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 90	1.6	2

4	285 POSTER MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 92	1.6	2
3	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii266-72	10.3	11
2	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , 2008 , 19 Suppl 5, v103-7	10.3	67
1	Parotid gland metastasis of a breast cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 264-5	3.6	13